Company Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
5 ^USD	0.00%		+5.49%	+64.01%

04-18	Ladenburg Thalmann Adjusts Aileron Therapeutics Price Target to $19 From $9, Maintains Buy Rating	MT
04-15	Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.

Number of employees: 15

Managers	Title	Age	Since
Brian Windsor CEO	Chief Executive Officer	57	23-10-30
Charles T. Garner DFI	Director of Finance/CFO	48	23-09-30
David Annis CTO	Chief Tech/Sci/R&D Officer	51	07-10-31
Manuel Alves Aivado BRD	Director/Board Member	53	14-08-31
Liz Melone IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Josef H. Von Rickenbach CHM	Chairman	68	19-06-18
Alan Musso BRD	Director/Board Member	61	23-10-30
Brian Windsor CEO	Chief Executive Officer	57	23-10-30
Reinhard Ambros BRD	Director/Board Member	67	13-05-31
Manuel Alves Aivado BRD	Director/Board Member	53	14-08-31
William Fairey BRD	Director/Board Member	59	23-10-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,972,512	16,107,726 ( 94.90 %)	0	94.90 %
Stock B	0	24,610	0	0

Name	Equities	%	Valuation
University of Texas Investment Management Co. 37.06 %	1,810,457	37.06 %	12 M $
Alerce Investment Management LP 17.00 %	830,466	17.00 %	6 M $
Geode Capital Management LLC 1.173 %	57,288	1.173 %	379 819 $
Vanguard Group, Inc. (Subfiler) 0.8252 %	40,314	0.8252 %	267 282 $
Gagnon Securities LLC 0.7767 %	37,947	0.7767 %	251 589 $
William Blair & Co. LLC 0.5792 %	28,297	0.5792 %	187 609 $
Renaissance Technologies LLC 0.5735 %	28,019	0.5735 %	185 766 $
KCK-US, Inc. 0.4573 %	22,341	0.4573 %	148 121 $
Josef H. Von Rickenbach 0.4559 %	22,273	0.4559 %	147 670 $
Sigma Planning Corp. 0.3394 %	16,580	0.3394 %	109 925 $

Aileron Therapeutics, Inc.

12407 North Mopac Expressway Suite 250

78758, Austin

http://www.aileronrx.com

address Aileron Therapeutics, Inc.(ALRN)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5 USD

Average target price

19 USD

Spread / Average Target

+280.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AILERON THERAPEUTICS, INC.	+64.01%	84.86M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.08%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.28%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs